Vyleesi Cost vs. Alternatives: Comparing Bremelanotide to Other HSDD Treatments

How Bremelanotide Works: The Melanocortin Mechanism

Bremelanotide activates melanocortin-4 receptors (MC4R) in the central nervous system, a pathway distinct from every other FDA-approved HSDD therapy. MC4R signaling modulates dopaminergic and oxytocinergic circuits involved in sexual arousal and desire. The drug does not target serotonin receptors directly, which separates it mechanistically from flibanserin.

MC4R Activation and Downstream Signaling

Preclinical work published in the Journal of Sexual Medicine demonstrated that MC4R agonism increases dopamine release in the medial preoptic area, a brain region linked to sexual motivation [1]. This dopaminergic effect occurs without the sedation or hypotension risk tied to serotonergic agents. Bremelanotide's affinity for MC4R is approximately 0.27 nM (Ki), making it a potent and selective agonist at this receptor subtype [2].

On-Demand Pharmacokinetics

Patients inject 1.75 mg subcutaneously into the abdomen or thigh at least 45 minutes before anticipated sexual activity. Peak plasma concentration (Tmax) occurs at roughly 1 hour post-injection [3]. The elimination half-life is approximately 2.7 hours. This short duration supports an as-needed model, and the drug is cleared before the next day. No dose titration is required.

Why the Mechanism Matters for Cost

Because bremelanotide is used on-demand rather than daily, total monthly expenditure scales with frequency of use. A patient using two doses per month spends roughly $430 to $480 at retail. A patient using the maximum 8 doses per month spends $1,700 to $1,920. This variable cost profile is unique among HSDD treatments and can work for or against the patient depending on sexual activity frequency.

Vyleesi Retail Pricing Breakdown

At pharmacy retail, a carton of four Vyleesi autoinjectors lists between $850 and $950 based on 2025 to 2026 pharmacy benchmarking data. No generic bremelanotide exists. AMAG Pharmaceuticals originally marketed the product; Palatin Technologies developed it and retains the patent portfolio.

Per-Dose Economics

Each autoinjector delivers a fixed 1.75 mg dose. That puts the single-dose retail cost at $212 to $238. For comparison, a single 100 mg flibanserin tablet at brand pricing (Addyi) costs approximately $27 to $33 per day, but the patient takes it every night regardless of planned sexual activity [4].

Manufacturer Savings Programs

Palatin has offered a patient savings card reducing out-of-pocket cost to as low as $0 for commercially insured patients meeting eligibility criteria, though specific program terms change annually. Patients without commercial insurance do not qualify for these programs and face the full retail price or must pursue patient assistance applications.

Monthly Cost Modeling: Vyleesi vs. Addyi

| Metric | Vyleesi (bremelanotide) | Addyi (flibanserin, brand) | Flibanserin (generic) | |---|---|---|---| | Doses per month | 2 to 8 (on-demand) | 30 (daily) | 30 (daily) | | Cost per dose (retail) | ~$215 to $240 | ~$27 to $33 | ~$1 to $2.70 | | Monthly cost at low use (2 doses) | ~$430 to $480 | ~$800 to $1,000 | ~$30 to $80 | | Monthly cost at moderate use (4 doses) | ~$860 to $960 | ~$800 to $1,000 | ~$30 to $80 | | Monthly cost at max use (8 doses) | ~$1,720 to $1,920 | ~$800 to $1,000 | ~$30 to $80 |

The crossover point sits at roughly 3 to 4 doses per month. Below that threshold, Vyleesi is cheaper than brand Addyi. Above it, Addyi's fixed monthly cost wins. Generic flibanserin, available since August 2023, undercuts both agents at every use level.

Efficacy Comparison: RECONNECT vs. BEGONIA and SNOWDROP

No randomized trial has compared bremelanotide directly to flibanserin. All efficacy comparisons rely on cross-trial analysis, which carries meaningful limitations.

The RECONNECT Trial

The RECONNECT trial (N=1,247) randomized premenopausal women with HSDD to bremelanotide 1.75 mg or placebo, used on-demand over 24 weeks [5]. Bremelanotide-treated patients reported a mean increase of 0.5 satisfying sexual events (SSEs) per month compared to placebo. The co-primary endpoint of desire, measured by the Female Sexual Distress Scale-Desire/Arousal/Orgasm (FSDS-DAO) Item 13, showed a statistically significant reduction in distress (P<0.001 vs. Placebo).

Approximately 35% of bremelanotide patients experienced nausea, the most common adverse event. Roughly 13% discontinued due to nausea [5]. Transient facial flushing and injection site reactions occurred in 20% and 13% of patients, respectively.

Flibanserin Trials: BEGONIA, DAISY, and SNOWDROP

The BEGONIA trial (N=1,087) evaluated flibanserin 100 mg nightly in premenopausal women with HSDD over 24 weeks [6]. The drug increased SSEs by 0.8 per month over placebo. The SNOWDROP trial (N=949) confirmed similar magnitude of benefit [7].

The Endocrine Society's 2019 position statement noted that "both flibanserin and bremelanotide have demonstrated statistically significant, albeit modest, improvements in sexual desire and reductions in distress associated with HSDD" [8]. Neither agent produced what clinicians would describe as a dramatic response.

Putting the Numbers Side by Side

| Outcome | Bremelanotide (RECONNECT) | Flibanserin (BEGONIA) | |---|---|---| | SSE increase vs. Placebo per month | +0.5 | +0.8 | | FSDS distress reduction | Significant (P<0.001) | Significant (P<0.001) | | Most common AE | Nausea (35%) | Dizziness (11%), somnolence (12%) | | Discontinuation for AEs | ~13% | ~10% | | Alcohol restriction | None | Contraindicated with alcohol |

Dr. Sheryl Kingsberg, a lead investigator on RECONNECT, stated: "Bremelanotide offers a mechanistically distinct, on-demand option for women who prefer not to take a daily medication or who cannot abstain from alcohol" [5].

Off-Label and Emerging Alternatives

Two off-label therapies and several pipeline agents compete with branded HSDD treatments. Their cost profiles differ substantially.

Bupropion (Off-Label)

Bupropion SR 150 mg twice daily has shown modest benefit for HSDD in small trials. A randomized controlled trial (N=232) found that bupropion improved desire scores by 1.9 points on the Changes in Sexual Functioning Questionnaire vs. Placebo over 12 weeks [9]. Generic bupropion costs $10 to $40 per month. No FDA approval exists for this indication.

Transdermal Testosterone (Off-Label)

The International Society for the Study of Women's Sexual Health (ISSWSH) 2018 process of care recommendations support off-label transdermal testosterone for postmenopausal women with HSDD after other causes have been excluded [10]. The ADORE trial and a Lancet meta-analysis of 36 RCTs (N=8,480) demonstrated that transdermal testosterone increased SSEs by approximately 0.85 per month vs. Placebo, with a favorable safety profile over 6 to 24 months [11]. Compounded testosterone cream costs $30 to $100 per month. No FDA-approved testosterone product exists for women.

Buspirone (Off-Label)

Buspirone 10 to 20 mg twice daily has limited evidence from small trials suggesting a modest positive effect on sexual desire. Cost is approximately $10 to $25 per month for generic formulations. Data quality is low, and no guidelines recommend it as a primary HSDD treatment.

Pipeline Agents

Several investigational compounds target female sexual dysfunction. These include oral melanocortin agonists under development to replicate bremelanotide's mechanism without the injection. No Phase 3 data are publicly available for any of these candidates as of May 2026.

Insurance Coverage and Access Barriers

Coverage for HSDD treatments remains inconsistent across payers. Both Vyleesi and Addyi frequently require prior authorization, step therapy, or specialty pharmacy dispensing.

Commercial Insurance Field

A 2021 analysis published in Contraception found that fewer than 50% of commercial formularies listed either bremelanotide or flibanserin without restrictions [12]. When coverage exists, plans typically require documentation of HSDD diagnosis by a qualified provider, failure of non-pharmacologic interventions, and in some cases, failure of the alternative FDA-approved agent before approving the requested drug.

Medicare and Medicaid

Medicare Part D plans may cover flibanserin as a self-administered oral medication but typically exclude Vyleesi as a self-injected agent under the Part D benefit. Medicaid coverage varies by state. Several states classify both agents as "lifestyle drugs" and exclude them from coverage entirely.

Strategies for Reducing Out-of-Pocket Costs

Patients and prescribers have a few options to lower the financial burden:

• Manufacturer savings programs: Check current Vyleesi and Addyi copay card availability directly through each brand's website. Terms change frequently.
• Generic flibanserin: Since August 2023, generic flibanserin has been available at $30 to $80 per month, making it the lowest-cost FDA-approved HSDD therapy.
• Appeals process: If a plan denies coverage, a peer-to-peer review citing the RECONNECT trial data and the patient's documented HSDD diagnosis may result in approval.
• Off-label generics: Bupropion and buspirone carry minimal cost but lack the regulatory evidence base of approved agents.

Safety Profile Comparison

Choosing between bremelanotide and flibanserin involves weighing different adverse event profiles, not just cost.

Nausea vs. CNS Depression

Bremelanotide's most limiting side effect is nausea, reported in 35% of RECONNECT participants [5]. This typically diminishes with repeated dosing. No alcohol restriction applies.

Flibanserin carries an FDA boxed warning for severe hypotension and syncope when combined with alcohol or moderate-to-strong CYP3A4 inhibitors [4]. The REMS program originally required prescriber certification, though the FDA removed the REMS prescriber certification requirement in 2019, retaining only the patient-focused elements.

Blood Pressure Effects

Bremelanotide causes a transient increase in systolic blood pressure of approximately 6 mmHg, peaking about 2 to 4 hours post-injection and resolving within 12 hours [3]. The FDA label contraindicates its use in patients with uncontrolled hypertension or known cardiovascular disease. This effect is clinically relevant for patients on antihypertensive medications.

Skin Hyperpigmentation

An uncommon but notable adverse effect of bremelanotide is focal skin darkening at injection sites or on the face and gums, reported in approximately 1% of patients during the RECONNECT trial [5]. This hyperpigmentation results from melanocortin-1 receptor (MC1R) cross-activation and may not fully resolve after discontinuation. Patients should be counseled about this possibility before starting therapy.

Who Is the Best Candidate for Each Option?

The ISSWSH 2018 process of care algorithm recommends evaluating biopsychosocial factors before prescribing any HSDD pharmacotherapy [10]. Medication choice should follow a shared decision-making conversation addressing cost, dosing preference, comorbidities, and side effect tolerance.

Bremelanotide May Fit Best When

• The patient prefers on-demand dosing over daily medication
• Alcohol use is regular and the patient is unwilling to abstain
• Sexual activity is infrequent (2 to 3 times per month), keeping costs lower
• The patient has no history of uncontrolled hypertension

Flibanserin (Generic) May Fit Best When

• Cost is the primary concern and the patient tolerates daily dosing
• The patient is willing to avoid alcohol
• Nausea intolerance would make bremelanotide impractical
• The patient prefers oral administration to injections

Off-Label Options May Fit Best When

• The patient has failed or declined both FDA-approved agents
• Budget constraints make even generic flibanserin difficult
• A comorbid condition like depression makes bupropion a dual-benefit choice

Dr. Anita Clayton, a co-investigator on HSDD trials, noted: "Clinicians should present all available options, including off-label therapies, to give women genuine agency in choosing a treatment that fits their life" [13].

The Bottom Line on Cost per Clinical Outcome

No cost-effectiveness analysis comparing bremelanotide to flibanserin has been published in a peer-reviewed journal as of May 2026. Rough modeling suggests that for a patient using bremelanotide twice monthly, the per-SSE cost at retail is approximately $860 to $960 divided by 0.5 incremental SSEs, yielding roughly $1,720 to $1,920 per additional SSE per month. Generic flibanserin at $50 per month divided by 0.8 incremental SSEs yields roughly $63 per additional SSE per month. These numbers lack the rigor of formal health-economic analysis but illustrate the magnitude of the cost gap when a generic alternative is available.

Patients starting HSDD pharmacotherapy should have a follow-up evaluation at 8 to 12 weeks to assess treatment response, per ISSWSH recommendations [10].